Vitiligo
Conditions
Brief summary
Assessment of the level of JAK1 in both vitiligo and psoriasis patients before and after treatment with NB-UVB which is considered a gold standard therapy for both diseases.
Interventions
OTHERskin biopsy
Two (4 mm) punch skin biopsies were taken from the 20 patients; one prior to the initiation of phototherapy and the other after the last session (from the same site). One skin biopsy was taken from the skin of each of the 10 control healthy participants. Skin biopsy specimens were preserved in Radio-Immunoprecipitation Assay (RIBA) buffer.
Sponsors
Cairo University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* age above 12 years of age. * psoriasis vulgaris or non-segmental vitiligo * patients who received no systemic or topical treatment at least 6 weeks prior to enrollment into the study.
Exclusion criteria
* psoriasis patients with erythrodermic psoriasis, pustular psoriasis or associated psoriatic arthritis * vitiligo patients with segmental or universal vitiligo were excluded from the study. * any patient with a photosensitive disorder or any contraindication to phototherapy exposure, e.g., history or presence of malignant or premalignant skin lesions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measurement of the tissue level of JAK1 in both vitiligo and psoriasis patients before and after treatment with NB-UVB | 1 year |
Outcome results
None listed